Tongue Cancer
Tongue cancer is treated as a distinct entity within oral cavity disease because of its anatomy, its patterns of spread and its functional consequences for speech and swallowing.
Disease categories
Major disease categories
- Oral tongue (anterior two-thirds) carcinoma
- Base of tongue carcinoma
Molecular
Molecular considerations
Molecular features overlap with oral cavity squamous cell carcinoma generally. Base of tongue tumours fall within the oropharynx and therefore raise HPV status.
Markers commonly discussed in tongue cancer
- TP53
- CDKN2A
- PIK3CA
- p16 / HPV (base of tongue)
- PD-L1
Not exhaustive, and not every marker is assessed in every patient. Which of these is relevant depends on the individual case and should be discussed with the treating team.
Testing
Genomic testing considerations
Site-appropriate testing, including HPV assessment for base of tongue disease.
Germline
Germline considerations
Considered in unusually young presentations.
Molecular monitoring
ctDNA and liquid biopsy considerations
Investigational, with more interest in HPV-associated base of tongue disease.
Single-cell & computation
Single-cell and algorithmic approaches
Single-cell sequencing in head and neck cancer is used to characterise immune exclusion and the stromal compartment, both of which vary substantially between tumours that look similar histologically. Single-cell DNA analysis contributes to field-change questions — whether a second lesion is a recurrence or an independent primary, which clonal analysis can often settle. Algorithm work includes HPV integration site analysis, deconvolution of immune composition from bulk expression, and viral circulating-DNA trajectory modelling.
Decisions
Treatment decision questions
Questions worth raising with a treating team when a decision is being made:
- Is the subsite specified as oral tongue or base of tongue?
- If base of tongue, has HPV status been assessed?
Resistance
Resistance and recurrence questions
- Has recurrence been distinguished from a second primary?
Trials
Clinical trial considerations
Subsite and HPV status affect eligibility.
When a precision oncology review may help
A review is most useful where the standard pathway has been exhausted or where the picture is more complicated than a protocol accounts for — rare presentations, treatment resistance, complex or apparently contradictory molecular findings, or a decision between several defensible options.
The output is a structured analysis and a set of questions for the treating team. It is not treatment, and it does not replace the treating oncologist.